Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €66.80 EUR
Change Today -1.90 / -2.76%
Volume 130.4K
MOR On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 3:35 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

morphosys ag (MOR) Snapshot

Open
€68.92
Previous Close
€68.70
Day High
€69.39
Day Low
€66.66
52 Week High
12/8/14 - €90.00
52 Week Low
03/26/15 - €54.30
Market Cap
1.8B
Average Volume 10 Days
114.7K
EPS TTM
€1.41
Shares Outstanding
26.5M
EX-Date
--
P/E TM
47.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for MORPHOSYS AG (MOR)

Related News

No related news articles were found.

morphosys ag (MOR) Related Businessweek News

No Related Businessweek News Found

morphosys ag (MOR) Details

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of musculoskeletal diseases, Alzheimer‘s disease, and rheumatoid arthritis. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies in the area of inflammatory diseases and oncology. The company’s proprietary product candidates include MOR103, an antibody that is in phase Ib trial for multiple sclerosis; MOR202, a therapeutic antibody that is in phase I/II trial for the treatment of multiple myeloma; and MOR208, which is in phase II clinical trials for patients suffering from diffuse large B-cell lymphoma. MorphoSys AG has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation for the co-development of the cancer program MOR202. The company was founded in 1992 and is headquartered in Martinsried, Germany.

354 Employees
Last Reported Date: 05/6/15
Founded in 1992

morphosys ag (MOR) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €751.2K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €509.6K
Chief Development Officer and Member of Manag...
Total Annual Compensation: €504.5K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €499.5K
Compensation as of Fiscal Year 2014.

morphosys ag (MOR) Key Developments

Morphosys AG to Present Data on Proprietary Programs at 20th Congress of the European Hematology Association

Morphosys AG announced the publication of three MorphoSys abstracts which were submitted to the 20th Congress of the European Hematology Association (EHA) to take place from June 11 - 14 in Vienna, Austria. The abstracts include pre-clinical and clinical data on the company's proprietary drug candidate MOR202 from a Phase 1/2a study in patients with multiple myeloma and updated clinical data for the MOR208 program. Abstract EHA-3357: A phase 1/2a study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma. The presentation will include the in the abstract described safety results and additional first efficacy results. The oral presentation will take place on June 14, 2015. Abstract EHA-3452: Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide. The poster presentation will take place on June 13, 2015. Abstract #E990: A phase 2a study of single-agent MOR208, an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). The abstract will be on display on the e-poster screens from June 12, 2015 to June 13, 2015.

Morphosys AG Elects New Supervisory Board Members

MorphoSys AG announced that its shareholders elected Ms. Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich as new members of the Supervisory Board. The company announced that Dr. Walter Blättler, Dr. Daniel Camus and Dr. Geoffrey Vernon resigned as Supervisory Board Members.

Morphosys AG Presents at BioEquity Europe 2015, May-19-2015 05:20 PM

Morphosys AG Presents at BioEquity Europe 2015, May-19-2015 05:20 PM. Venue: InterContinental Vienna, Vienna, Austria. Speakers: Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Jens Holstein, Chief Financial Officer and Member of Management Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOR:GR €66.80 EUR -1.90

MOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €10.66 EUR +0.185
Genmab A/S kr596.50 DKK -2.00
ImmunoGen Inc $8.98 USD -0.04
Intrexon Corp $42.12 USD +1.24
XOMA Corp $3.52 USD -0.06
View Industry Companies
 

Industry Analysis

MOR

Industry Average

Valuation MOR Industry Range
Price/Earnings 50.2x
Price/Sales 15.4x
Price/Book 4.7x
Price/Cash Flow 50.7x
TEV/Sales 13.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG, please visit www.morphosys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.